Seifert, Robert
Kessel, Katharina
Schlack, Katrin
Weber, Manuel
Herrmann, Ken
Spanke, Maximilian
Fendler, Wolfgang P.
Hadaschik, Boris
Kleesiek, Jens
Schäfers, Michael
Weckesser, Matthias
Boegemann, Martin
Rahbar, Kambiz http://orcid.org/0000-0002-4591-4055
Funding for this research was provided by:
Westfälische Wilhelms-Universität Münster
Article History
Received: 27 June 2020
Accepted: 13 September 2020
First Online: 24 September 2020
Compliance with ethical standards
:
: KR has received consultant fees from Bayer and lectureship fees from Janssen Cilag, Amgen, AAA, and SIRTEX. KR is a clinical consultant for ABX. The University of Muenster has received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany for KR. MB has received consultant and lectureship fees from Bayer, Janssen Cilag, Astellas, ABX, Sanofi, Eisai, EUSApharm, Pfizer, BMS, MSD, AstraZeneca, Merck, Amgen, Novartis, Exelixis, and Roche. WPF is a consultant for Endocyte and BTG, and he received fees from RadioMedix and Bayer outside of the submitted work. BAH has had advisory roles for ABX, Astellas, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, German Cancer Aid, German Research Foundation, and Janssen R&D; and has received compensation for travel from Astellas, AstraZeneca, and Janssen R&D.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The retrospective analysis of the Muenster cohort was approved by the local ethics committee (No. 2016-585-f-S, Ethikkommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster). The retrospective analysis of the Essen cohort was approved by the local ethics committee (No. 19-8570-BO).